WGU D027 | OA
OBJECTIVE ASSESSMENT - EX AM
Advanced
Pathopharmacological
Foundations
WGU D027 | OA Complete
100 100% 2026 /
QUESTIONS VERIFIED ANSWERS
2027
EDITION
TOPICS COVERED
• Pathophysiology of Major Disease States • Neurologic & Endocrine Pharmacology
• Pharmacokinetics & Pharmacodynamics • Infectious Disease & Immunopharmacology
• Cardiovascular & Respiratory Pharmacology
COVER PAGE - 1
, SECTION 1 | PATHOPHYSIOLOGICAL PRINCIPLES, PHARMACOKINETICS, AND
PHARMACODYNAMICS | Q1-Q20 | WGU D027 ADVANCED PATHOPHARMACOLOGICAL
FOUNDATIONS OA 2026/2027
Q1. Question 1 of 100
A 42-year-old female patient is initiated on phenytoin therapy for the management of
generalized tonic-clonic seizures. Genetic testing reveals that she possesses a homozygous
CYP2C9*3 polymorphism, which significantly decreases enzyme activity.
A. Increase the standard maintenance dose due to rapid enzymatic clearance.
B. Reduce the standard maintenance dose to avoid toxicity from impaired metabolism.
C. Substitute phenytoin with fosphenytoin to bypass the CYP2C9 pathway entirely.
D. Maintain standard dosing but monitor plasma levels every six months only.
Correct Answer: B
Rationale:
The CYP2C9 enzyme is the primary metabolic pathway for phenytoin. Patients who carry the homozygous
CYP2C9*3 polymorphism exhibit profoundly reduced metabolic clearance of phenytoin, leading to
dangerously high serum concentrations and subsequent neurotoxicity at standard doses. Therefore, a
proactive reduction in the maintenance dose is required to ensure patient safety, whereas changing to
fosphenytoin does not resolve the issue since fosphenytoin is a prodrug that converts directly into phenytoin.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 2 of 96
, Q2. Question 2 of 100
A 65-year-old male patient requiring anticoagulation for atrial fibrillation undergoes
genotyping prior to initiating warfarin therapy. The results indicate a highly sensitive
VKORC1 A/A genotype alongside normal CYP2C9 function.
A. A higher-than-average starting dose of warfarin is indicated due to target receptor resistance.
B. A standard initial dose should be administered alongside an aggressive loading protocol.
C. A lower-than-average starting dose of warfarin is required to prevent profound over-
anticoagulation.
D. Warfarin should be completely avoided because the patient will fail to achieve therapeutic INR
ranges.
Correct Answer: C
Rationale:
The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit 1, which is the direct molecular
target of warfarin. The A/A genotype represents a low-expression phenotype, meaning the patient possesses
fewer target enzymes and requires a significantly lower baseline dose of warfarin to achieve the same
therapeutic level of anticoagulation; starting with standard doses would cause rapid, dangerous elevations in
INR and severe bleeding risks.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 3 of 96
, Q3. Question 3 of 100
An 58-year-old male patient with biopsy-confirmed Child-Pugh Class C hepatic cirrhosis
presents to the clinic presenting with severe osteoarthritic pain. The provider reviews the
pharmacokinetics of oral analgesic agents under consideration.
A. Oral medications with a high baseline first-pass effect will demonstrate decreased systemic
bioavailability.
B. Oral medications with a high baseline first-pass effect will demonstrate increased systemic
bioavailability.
C. Hepatic blood flow changes will exclusively alter the distribution volume without impacting drug half-
life.
D. Phase II conjugation pathways are completely preserved and can handle unlimited therapeutic drug
volumes.
Correct Answer: B
Rationale:
In advanced cirrhosis, significant intrahepatic shunts and a loss of functional hepatocytes dramatically reduce
the liver's ability to extract drugs during their first pass through the portal circulation. Consequently,
medications that normally undergo extensive first-pass hepatic metabolism will enter the systemic circulation
in much higher amounts than anticipated, increasing bioavailable drug fractions and the risk of systemic
toxicity.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 4 of 96
OBJECTIVE ASSESSMENT - EX AM
Advanced
Pathopharmacological
Foundations
WGU D027 | OA Complete
100 100% 2026 /
QUESTIONS VERIFIED ANSWERS
2027
EDITION
TOPICS COVERED
• Pathophysiology of Major Disease States • Neurologic & Endocrine Pharmacology
• Pharmacokinetics & Pharmacodynamics • Infectious Disease & Immunopharmacology
• Cardiovascular & Respiratory Pharmacology
COVER PAGE - 1
, SECTION 1 | PATHOPHYSIOLOGICAL PRINCIPLES, PHARMACOKINETICS, AND
PHARMACODYNAMICS | Q1-Q20 | WGU D027 ADVANCED PATHOPHARMACOLOGICAL
FOUNDATIONS OA 2026/2027
Q1. Question 1 of 100
A 42-year-old female patient is initiated on phenytoin therapy for the management of
generalized tonic-clonic seizures. Genetic testing reveals that she possesses a homozygous
CYP2C9*3 polymorphism, which significantly decreases enzyme activity.
A. Increase the standard maintenance dose due to rapid enzymatic clearance.
B. Reduce the standard maintenance dose to avoid toxicity from impaired metabolism.
C. Substitute phenytoin with fosphenytoin to bypass the CYP2C9 pathway entirely.
D. Maintain standard dosing but monitor plasma levels every six months only.
Correct Answer: B
Rationale:
The CYP2C9 enzyme is the primary metabolic pathway for phenytoin. Patients who carry the homozygous
CYP2C9*3 polymorphism exhibit profoundly reduced metabolic clearance of phenytoin, leading to
dangerously high serum concentrations and subsequent neurotoxicity at standard doses. Therefore, a
proactive reduction in the maintenance dose is required to ensure patient safety, whereas changing to
fosphenytoin does not resolve the issue since fosphenytoin is a prodrug that converts directly into phenytoin.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 2 of 96
, Q2. Question 2 of 100
A 65-year-old male patient requiring anticoagulation for atrial fibrillation undergoes
genotyping prior to initiating warfarin therapy. The results indicate a highly sensitive
VKORC1 A/A genotype alongside normal CYP2C9 function.
A. A higher-than-average starting dose of warfarin is indicated due to target receptor resistance.
B. A standard initial dose should be administered alongside an aggressive loading protocol.
C. A lower-than-average starting dose of warfarin is required to prevent profound over-
anticoagulation.
D. Warfarin should be completely avoided because the patient will fail to achieve therapeutic INR
ranges.
Correct Answer: C
Rationale:
The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit 1, which is the direct molecular
target of warfarin. The A/A genotype represents a low-expression phenotype, meaning the patient possesses
fewer target enzymes and requires a significantly lower baseline dose of warfarin to achieve the same
therapeutic level of anticoagulation; starting with standard doses would cause rapid, dangerous elevations in
INR and severe bleeding risks.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 3 of 96
, Q3. Question 3 of 100
An 58-year-old male patient with biopsy-confirmed Child-Pugh Class C hepatic cirrhosis
presents to the clinic presenting with severe osteoarthritic pain. The provider reviews the
pharmacokinetics of oral analgesic agents under consideration.
A. Oral medications with a high baseline first-pass effect will demonstrate decreased systemic
bioavailability.
B. Oral medications with a high baseline first-pass effect will demonstrate increased systemic
bioavailability.
C. Hepatic blood flow changes will exclusively alter the distribution volume without impacting drug half-
life.
D. Phase II conjugation pathways are completely preserved and can handle unlimited therapeutic drug
volumes.
Correct Answer: B
Rationale:
In advanced cirrhosis, significant intrahepatic shunts and a loss of functional hepatocytes dramatically reduce
the liver's ability to extract drugs during their first pass through the portal circulation. Consequently,
medications that normally undergo extensive first-pass hepatic metabolism will enter the systemic circulation
in much higher amounts than anticipated, increasing bioavailable drug fractions and the risk of systemic
toxicity.
WGU D027 Advanced Pathopharmacological Foundations OA — 2026/2027 | Passing Score: 75% | Page 4 of 96
